Trial Summary:

A phase III trial to establish overall survival and failure-free survival of patients with high risk and advanced stage endometrial carcinoma, treated after surgery with concurrent radiotherapy and chemotherapy, followed by adjuvant chemotherapy, in comparison with patients treated with pelvic radiation alone.

Supported By:

Cancer Australia, NHMRC, TROG, Hospira, Dutch Cooperative Gynecologic Oncology Group (CGOG)

Eligibility:

Histologically confirmed endometrial carcinoma, with one of the following postoperative International Federation of Gynecology and Obstetrics (FIGO) stages and grade:
a. Stage IB grade 3 with documented Lymphatic Vascular Space Invasion (LVSI) 
b. Stage 1C grade 3 
c. Stage II grade 3 
d. Stage IIIA or IIIC (IIIA based on peritoneal cytology alone is only eligible if grade 3) 
e. Stage IB or IC, stage II or stage III with serous or clear cell histology

Registration ID:

ACTRN12609000369224, NCT00411138

Participation:

Australia, Netherlands, UK, Canada

Australian Lead Group:

ANZGOG

Status:

In follow-up

Activation Date:

11/07/2018

Chairs:

Prof Linda Mileshkin (Australia and New Zealand)

Contact:

portec-3.study@sydney.edu.au